The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

J Am Acad Dermatol. 2020 Nov;83(5):1523-1526. doi: 10.1016/j.jaad.2020.06.1014. Epub 2020 Jul 2.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Betacoronavirus / immunology
  • Biological Products / administration & dosage
  • Biological Products / adverse effects*
  • COVID-19
  • Clinical Decision-Making
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / prevention & control
  • Coronavirus Infections / transmission
  • Humans
  • Interleukin-23 Subunit p19 / antagonists & inhibitors*
  • Interleukin-23 Subunit p19 / metabolism
  • Odds Ratio
  • Pandemics / prevention & control
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / prevention & control
  • Pneumonia, Viral / transmission
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Respiratory Tract Infections / chemically induced
  • Respiratory Tract Infections / epidemiology*
  • Respiratory Tract Infections / immunology
  • Respiratory Tract Infections / prevention & control
  • Risk Assessment
  • SARS-CoV-2
  • Signal Transduction / drug effects
  • Signal Transduction / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • IL23A protein, human
  • Interleukin-23 Subunit p19
  • guselkumab
  • risankizumab
  • tildrakizumab